Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jubilant Revenues Flat On LSI Decline

LSI Business To Be Demerged As Part Of Restructuring

Executive Summary

Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in the LSI business and FDA action at two manufacturing units.

You may also be interested in...



Alembic Q2 Gets Sartans Shot

Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.

Jubilant Considers Splitting Itself Into Two for Greater Focus

Jubilant’s board is considering whether to create separate entities for its Pharmaceuticals and Life Science Ingredients business segments to give each greater focus.

The Quality Lowdown: Valsartan Options, Supply Chain Warnings, Button Cameras

Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel